Last reviewed 23 July 2021

The Health and Safety Executive (HSE) has received an application for authorisation for 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (OPEO) (CAS: 9036-19-5). Use of 4-tert-OPnEO in the development of gene therapies.

Under Article 64 of UK REACH, the HSE can obtain and use additional information on possible alternatives or technologies as part of the opinion forming process, hence this public consultation.

The HSE has requested information by 8 September 2021. More information can be found on the HSE website.